linjc16/ctgov huggingface dataset:
Effect Of Delta Sodium on the Postoperative Outcomes in Liver Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
We analyzed the association of delta sodium levels with their effect on post liver transplant outcomes in consecutive patients undergoing liver transplantation. Records were analyzed for electrolytes and outcome measures, and data was analyzed.

Detailed Description
-----------------
Preoperative hyponatremia was identified in patients. The mean change in sodium in hyponatremic patients was compared with inpatients with normal sodium levels. The impact of the delta sodium levels with short-term outcomes, such as duration of intubation, intensive care unit length of stay were analyzed with univariate and multivariate logistic regression analyses.

Official Title
-----------------
Effect of Perioperative Delta Sodium on Outcomes in Liver Transplant Recipients

Conditions
-----------------
Liver Transplant; Complications, Perioperative/Postoperative Complications, Electrolyte Disturbance

Intervention / Treatment
-----------------
* Other: Collecting sodium reports and outcome measures


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All liver transplant recipients between Jan 2011 to Jan 2017 Records available Exclusion Criteria: Acute fulminant liver failure All patients less than 18 years Re operated cases Pregnant patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Liver Transplant Recipients<br>All elective liver transplant recipients done between study period | Other: Collecting sodium reports and outcome measures<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in serum sodium in liver transplant recipients | difference between baseline and postoperative sodium in liver transplant recipients | 1 day | 
| post transplant mortality | post transplant mortality after liver transplantation | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| post operative neurological complications | Post operative neurological complications after liver transplantation | 1 month | 
| duration of mechanical ventilation | duration of mechanical ventilation after liver transplantation | 1 month | 
| Duration of hospital stay | Hospital stay after liver transplantation | 1 month | 
| Duration of ICU stay | Duration of ICU stay after liver transplantation | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sodium, liver transplantation, perioperative sodium
Relationship Between Oral Health and Diabetes

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the state of knowledge and practices in oral health of diabetic patients through the use of two questionnaires. It is also to analyse the link between the oral health status and the profile of diabetic patient, by carrying out an oral assessment for voluntary patients.

Official Title
-----------------
Oral Health and Diabetes: Relationship Between Knowledge, Practices and Oral Health Status in Patients Followed in the Diabetes Department at the Montpellier University Hospital.

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - All diabetic patients over 18 coming to the CHU Lapeyronie Exclusion criteria: -Non diabetic patients, diabetic patients under 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diabetic patients over 18 from the CHU Lapeyronie<br>Diabetic patients over 18 from the CHU Lapeyronie | Other: Questionnaire<br>* Two questionnaires used to assess the state of knowledge and practices in oral health. An oral assessment will be carried out for voluntary patients.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oral health knowledge and practice questionnaire score. | Oral health knowledge and practice questionnaire score. | 1 day | 
| Number of missing and decayed teeth on the oral examination and clinical signs in diabetology. | Number of missing and decayed teeth on the oral examination and clinical signs in diabetology. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oral hygiene, Public Health, Patients coming to the CHU Lapeyronie for consultation or those being hospitalised there, Prevention, Telemedicine
A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
To demonstrate bioequivalence of fesoterodine 4 mg tablets manufactured at Vega Baja, versus Zwickau.

Official Title
-----------------
An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™), Manufactured At Zwickau Versus Vega Baja, In Healthy Subjects.

Conditions
-----------------
Treatment of Overactive Bladder

Intervention / Treatment
-----------------
* Drug: Fesoterodine
* Drug: Fesoterodine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male and/or female subjects Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs). Exclusion Criteria: Subjects with evidence or history of clinically significant urologic diseases A positive urine drug screen Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Reference<br>fesoterodine (Toviaz™ 4 mg) tablet manufactured at Zwickau (Reference) | Drug: Fesoterodine<br>* A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg<br>* Other names: Toviaz 4 mg;|
| Other: Test<br>fesoterodine (Toviaz™ 4 mg) tablet manufactured at Vega Baja (Test) | Drug: Fesoterodine<br>* A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg<br>* Other names: Toviaz 4 mg;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCinf, AUClast, and Cmax of 5-HMT |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tmax and half-life of 5-HMT as data permit |  | 6 weeks | 
| Safety laboratory tests and adverse events |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bioequivalence
The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate circulating tumor DNA (ctDNA) as a predictive and surveillant method for tumor recurrence in stage II and III colorectal cancer (CRC).

Detailed Description
-----------------
This study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of a short-term disease recurrence in surgical resective stage II and stage III colorectal cancer (CRC). The investigators will recruit newly diagnosed CRC patients, systematically collect their blood samples at the following time point: before surgery, one week after surgery, every three months for the first year and every six months for the second year, which are coincidence with the recommended clinical follow-up. Patients' outcome and survival will be tracked. These study will permit assessment of ctDNA as a predictive and surveillant method for a short-term (two years) tumor recurrence in comparison with other parameters.

Official Title
-----------------
The Implication of Plasma Circulating Tumor DNA (ctDNA) in the Recurrence Surveillance of Stage II and III Colorectal Cancer: a Prospective Study

Conditions
-----------------
Colorectal Cancer, ctDNA, Surveillance

Intervention / Treatment
-----------------
* Diagnostic Test: ctDNA test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female ≥ 18 years of age on the day of signing informed consent. Patients must have histologically confirmed stage II or IIIcolorectal cancer. Patients must receive radical resection. Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study. Exclusion Criteria: Patient has severe anemia. Patients received neoadjuvant treatment. Patients received blood transfusion two weeks before or during the surgical resection. Patient has any other conditions, which, in the opinion of the Investigator, would interfere with the evaluation of the subject

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ctDNA test group<br> | Diagnostic Test: ctDNA test<br>* ctDNA test to find some possible mutation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease Free Survival |  | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal Cancer, ctDNA, Surveillance
Appetite and Related Factors in Patients With ALS

Study Overview
=================
Brief Summary
-----------------
Chinese cnaq scale was used to evaluate the appetite changes of Chinese ALS patients; Objective to investigate the related factors of appetite changes in ALS patients; Objective to investigate the effect of anorexia on the progression and survival of ALS patients.

Detailed Description
-----------------
With the consent of the original author, the scale was translated and back translated, and the Chinese version of the scale was determined after communication and confirmation with the original author. Cnaq was used to measure the appetite of the patients, and hads was used to measure the anxiety and depression of the patients; Analyze the proportion of loss of appetite in ALS group, compare the differences of clinical characteristics such as ALSFRS-R score, weight, BMI value, cognitive status such as ECAs score between patients with loss of appetite and patients without loss of appetite in ALS group, and conduct correlation analysis. The patients were followed up every three months until they were unable to eat or end-point events (invasive ventilator or death), and the correlation between cnaq and disease progression and survival was analyzed.

Official Title
-----------------
Detection of Appetite and Analysis of Related Factors in Patients With Amyotrophic Lateral Sclerosis (ALS)

Conditions
-----------------
Amyotrophic Lateral Sclerosis

Intervention / Treatment
-----------------
* Diagnostic Test: Appetite rating scale CNAQ


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ALS patients diagnosed as probable, or definite according to the revised El Escorial criteria Exclusion Criteria: there are other chronic consumption diseases such as severe digestive system diseases, thyroid diseases, diabetes and so on.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CNAQ≤28<br>ALS patients with CNAQ ≤ 28 | Diagnostic Test: Appetite rating scale CNAQ<br>* Chinese version of Appetite rating scale CNAQ<br>|
| CNAQ>28<br>ALS patients with CNAQ > 28 | Diagnostic Test: Appetite rating scale CNAQ<br>* Chinese version of Appetite rating scale CNAQ<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ALSFRS-R score |  | 3 months | 
| ALSFRS-R score |  | 6 months | 
| ALSFRS-R score |  | 12 months | 
| Food intake | Inability to eat | 3 months | 
| Food intake | Inability to eat | 6 months | 
| Food intake | Inability to eat | 12 months | 
| invasive ventilator or death | end point events | 3 months | 
| invasive ventilator or death | end point events | 6 months | 
| invasive ventilator or death | end point events | 12 months |
The Effects of Processed Whole Orange on Subjective Ratings of Satiety

Study Overview
=================
Brief Summary
-----------------
The study is a human dietary test meal study that is a randomized, controlled, double blind, cross over design with 3 intervention arms that will investigate the subjective ratings of satiety in response to different levels of processed whole orange compared with a sugar-matched isocaloric control

Official Title
-----------------
The Effect of Different Doses of Processed Whole Orange on Subjective Ratings of Satiety

Conditions
-----------------
Self Reported Ratings of Hunger

Intervention / Treatment
-----------------
* Other: Orange flavored beverage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gender: male or female Age at start of the study: males and females ≥ 21and ≤ 65 years Females taking contraceptive pill or post menopausal Body Mass Index (BMI) ≥ 18.5 and ≤ 27 kg/m2 Apparently healthy: measured by questionnaire, no reported current or previous -metabolic diseases or chronic gastrointestinal disorders Reported dietary habits: no medically prescribed diet, no slimming diet within the past 3 months, used to eating 3 meals a day Reported intense sporting activities ≤ 10h/w Reported alcohol consumption ≤21 units/w Informed consent signed Recruitment form filled out Exclusion Criteria: Smoking Premenopausal females not taking the contraceptive pill Dislike, allergy or intolerance to test products Possible eating disorder (measured by SCOFF questionnaire score >1) Eating habits questionnaire score >14 Reported medical treatment that may affect eating habits/satiety Food allergies or intolerance

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Orange flavored beverage - Test1<br>240ml processed whole orange low dose | Other: Orange flavored beverage<br> <br> |
| Experimental: Orange flavored beverage - Test2<br>240ml processed whole orange high dose | Other: Orange flavored beverage<br> <br> |
| Placebo Comparator: Orange flavored beverage - Placebo<br>240ml orange beverage | Other: Orange flavored beverage<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self reported ratings of hunger and fullness |  | 0-2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Satiety, beverage, crossover
Dissociative Disorders in Obesity (Dissobe)

Study Overview
=================
Brief Summary
-----------------
THe aim of this study is to determine the frequency of dissociative tendencies in the obese population treated at the CELIOBE (Liberal Center for Obesity Support) at Hôpital Privé La Louvière among patients consulting for the first time and looking for a medical or surgical course. The DES scale of Carlson and Putman will be used.

Official Title
-----------------
Dissociative Disorders in Obesity

Conditions
-----------------
Obesity, Dissociative Disorder

Intervention / Treatment
-----------------
* Behavioral: Obese patient following a medical course


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 Obesity defined by a Body Mass Index (BMI) ≥ 30 kg / m2 Patient seen in consultation at CELIOBE for the first time for the management of an overweight problem, wishing for surgical or medical care Patient having been informed and not opposing to this research Patient affiliated or beneficiary of a social security scheme Exclusion Criteria: Psychotic antecedents: Schizophrenia, Schizoaffective disorders, Hallucinatory psychoses, Brief psychotic attacks Addictive behaviors (alcohol, drug addiction) Drug use Taking antipsychotics and mood stabilizers Dissociative identity disorders proven Bipolar disorders or severe mental illness Understanding troubles Protected patient: Major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision; Hospitalized without consent Pregnant, breastfeeding or parturient woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obese patient following a medical course<br> | Behavioral: Obese patient following a medical course<br>* Questionnaires for the assessment of dissociative disorders in obese patients : DES scale of Carlson and Putman, SDQ-20 of Nijenhuis, comorbidities, Dutch Eating Behaviour Questionnaire (DEBQ), questionnaire of Rosenberg<br>|
| Obese patient following a surgical course<br> | Behavioral: Obese patient following a medical course<br>* Questionnaires for the assessment of dissociative disorders in obese patients : DES scale of Carlson and Putman, SDQ-20 of Nijenhuis, comorbidities, Dutch Eating Behaviour Questionnaire (DEBQ), questionnaire of Rosenberg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The degree of dissociative tendencies | The degree of dissociative tendencies measured by the Carlson and Putman DES scale. | 1 day |
Pilot Study of Human Tear Proteins

Study Overview
=================
Brief Summary
-----------------
The significance of our study is in the importance of understanding the quality and quantity of proteins in the human tear film from diseased and non-diseased patients. This pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion.

Official Title
-----------------
Analysis of Human Tear Proteins: A Pilot Study to Describe the Tear Film Proteome of Patients Undergoing Ophthalmic Examination.

Conditions
-----------------
Eye Disease

Intervention / Treatment
-----------------
* Other: Eye Examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age and older able to cooperate with tear sample collection provide written informed consent Exclusion Criteria: special populations (children, pregnant or lactating females, prisoners, etc) refusal to sign sudy consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study Subject<br>Subjects receiving eye examination | Other: Eye Examination<br>* Subjects receiving eye examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plan Prospective Research | Pilot study will provide data to plan prospective research to better delineate the utility of tear proteins in diagnosing and following disease status in a non-invasive fashion. | Throughout study participation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ocular proteomics, eye disease, proteomics
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to collect pancreatic tissue, blood and urine from adults to study pancreatic abnormalities.

Detailed Description
-----------------
The aim of the study is to standardize, collect and share pancreatic cancer related information, to be used for research purposes only by researchers from different participating institutions/centers.

Official Title
-----------------
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic Cancer)

Conditions
-----------------
Pancreatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Person over 19 years of age, patient with a tissue-proven diagnosis of pancreatic cancer at the University of Alabama at Birmingham (UAB) University Hospital during the period, and cognitive ability to provide informed consent Exclusion Criteria: Person not 19 or older and have not had a tissue-proven diagnosis of pancreatic cancer.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To diagnose Pancreatic Cancer |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preventing patient form being misdiagnosed |  | 5 years |